BioWorld Asia

Sep. 22, 2004

BMS Drops Flamel’s Basulin; Shares Suffer 22 Percent Hit

It may be true that “two out of three ain’t bad” - but two pieces of good news and one seriously negative item added up to trouble on Wall Street for Flamel Technologies SA. (BioWorld International) Read More

Acambis Falls On Cancelled Smallpox Contract From CDC

Angiogenesis Study Turns Up Male Infertility Surprise Factor

CeNeS Reports Positive Phase III M6G Data In Post-Operative Pain

Active Biotech Seeking SEK150M In Convertible Debentures Issue

Genetic Markers Of Epidermis Cell Differentiation Identified

Novagali Pharma Completes Second Round For EUR14.2M

EU Medicines Guidelines Up For General Comment

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for March 16, 2026.

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

Keros reports beneficial effects of RKER-065 in ALS model

BioWorld Science

Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.

News in brief

BioWorld Asia

BioWorld Asia briefs for March 10, 2026

First-in-class POLG activator restores mtDNA across mutations

BioWorld Science

Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...